linerixibat

Indications

• pruritus associated with primary biliary cholangitis

Dosage

• 40 mg PO BID, 90 mg PO BID, 180 mg PO QD

Adverse effects

• diarrhea
• abdominal pain

Mechanism of action

• minimally absorbed oral small molecule ileal bile acid transporter inhibitor

Clinical trials

• phase 2 trial

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=53492727